Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients
with advanced cancer. The safety of these drugs will also be studied.
Pazopanib is designed to block different receptors in the cancer cells that ultimately are
responsible for the growth of the tumor and its blood vessels.
Everolimus is designed to block a protein called mTOR inside the cancer cells, which is also
involved in cancer growth.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
GlaxoSmithKline National Comprehensive Cancer Network